Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | COMT | P21964 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22402428 | 0.92 | PIK3CD (0.41) | PIK3CDCYP2D6SMN1; SMN2 | |
| SCHEMBL24856302 | 0.90 | PIK3CD (0.40) | PIK3CDCYP2D6SMN1; SMN2SLC2A1 | |
| SCHEMBL19286478 | 0.86 | PIK3CD (0.39) | PIK3CDCYP2D6SMN1; SMN2 | |
| SCHEMBL20317543 | 0.82 | CYP2D6 (0.37) | PIK3CDCYP2D6SMN1; SMN2ALDH1A1 | |
| SCHEMBL23277989 | 0.82 | DRD2 (0.39) | PIK3CD | |
| SCHEMBL23277808 | 0.82 | PIK3CD (0.31) | PIK3CDKDM4EALDH1A1GFERL3MBTL1 | |
| SCHEMBL24209746 | 0.82 | PIK3CD (0.61) | PIK3CDCYP2D6SMN1; SMN2L3MBTL1SLC2A1 | |
| SCHEMBL20438377 | 0.82 | PIK3CD (0.61) | PIK3CDCYP2D6SMN1; SMN2L3MBTL1SLC2A1 | |
| SCHEMBL2001262 | 0.82 | — | — | |
| SCHEMBL1621691 | 0.82 | PIK3CD (0.61) | PIK3CDCYP2D6SMN1; SMN2L3MBTL1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | AUBURN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | AUBURN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240018134-A1 | 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2024-01-18 | — | — | US | disclosed |
| US-20230272010-A1 | ANTIBACTERIAL SYNTHETIC-BIOINFORMATIC NATURAL PRODUCTS AND USES THEREOF | UNIV ROCKEFELLER (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230272010-A1 | ANTIBACTERIAL SYNTHETIC-BIOINFORMATIC NATURAL PRODUCTS AND USES THEREOF | UNIV ROCKEFELLER (US) | 2023-08-31 | — | — | US | disclosed |
| US-20220220069-A1 | COMPOUND USED AS SIRT6 SMALL-MOLECULE ALLOSTERIC ACTIVATOR AND PHARMACEUTICAL COMPOSITION THEREOF | SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20220153722-A1 | CDK2/5 DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220119445-A1 | SYNTHETIC CYCLIC PEPTIDES AND METHODS OF PREPARATION AND USE THEREOF | NATIONAL SCIENCE FOUNDATION | 2022-04-21 | — | — | US | disclosed |
| US-11254696-B2 | Dianilinopyrimidine compound for inhibiting kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2022-02-22 | — | — | US | disclosed |
| US-20210087213-A1 | DIANILINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2021-03-25 | — | — | US | disclosed |
| US-8394796-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-07-12 | — | — | US | disclosed |
| US-8173650-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173650-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8158625-B2 | Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120046278-A1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-02-23 | — | — | US | disclosed |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | US | disclosed |
| US-20100305084-A1 | BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | HOFFMAN-LA ROCHE INC. | 2010-12-02 | — | — | US | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220069-A1 | COMPOUND USED AS SIRT6 SMALL-MOLECULE ALLOSTERIC ACTIVATOR AND PHARMACEUTICAL COMPOSITION THEREOF | SIRT6, SIRT1, SIRT7 | PIK3CD 1209/4885CYP2D6 1070/4885SMN1; SMN2 1848/4885 |
| US-20210087213-A1 | DIANILINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY | ALK, BRAF, MUSK | PIK3CD 270/4885CYP2D6 627/4885SMN1; SMN2 641/4885 |
| US-20100305084-A1 | BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PI4K2B, PIK3CA, PIK3R2 | PIK3CD 4/4885CYP2D6 2177/4885SMN1; SMN2 3259/4885 |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | PIK3CD 3/4885CYP2D6 2699/4885SMN1; SMN2 2134/4885 |
| US-20120046278-A1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | TPMT, STAT6, IL4 | PIK3CD 1472/4885CYP2D6 125/4885SMN1; SMN2 4474/4885 |
| US-20240018134-A1 | 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders | SMARCC1, SMARCC2, SMARCA4 | PIK3CD 1516/4885CYP2D6 463/4885SMN1; SMN2 17/4885 |
| US-20230272010-A1 | ANTIBACTERIAL SYNTHETIC-BIOINFORMATIC NATURAL PRODUCTS AND USES THEREOF | LSS, NRDC, SPOUT1 | PIK3CD 2141/4885CYP2D6 2157/4885SMN1; SMN2 4501/4885 |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | VIP, PTMS, IAPP | PIK3CD 2609/4885CYP2D6 4595/4885SMN1; SMN2 3180/4885 |
| US-20220119445-A1 | SYNTHETIC CYCLIC PEPTIDES AND METHODS OF PREPARATION AND USE THEREOF | VIP, PTMS, IAPP | PIK3CD 2609/4885CYP2D6 4595/4885SMN1; SMN2 3180/4885 |
| US-20220153722-A1 | CDK2/5 DEGRADERS AND USES THEREOF | CDK2, CDK5, CDK5R1 | PIK3CD 1312/4885CYP2D6 3355/4885SMN1; SMN2 948/4885 |
| US-11254696-B2 | Dianilinopyrimidine compound for inhibiting kinase activity | ALK, BRAF, MUSK | PIK3CD 252/4885CYP2D6 669/4885SMN1; SMN2 693/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | PIK3CD 3/4885CYP2D6 2614/4885SMN1; SMN2 2248/4885 |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885CYP2D6 995/4885SMN1; SMN2 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.